NEW YORK, March 15, 2018 -- The Law Offices of Vincent Wong announce that class action lawsuits have been commenced in the United States District Court for the Eastern District of New York on behalf of investors who purchased Synergy Pharmaceuticals Inc. ("Synergy") (NASDAQ:SGYP) securities between November 10, 2016 and November 14, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-c/synergy-pharmaceuticals-inc?wire=3. There is no cost or obligation to you.
According to the complaints, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) the loan from CRG Partners III L.P. (“CRG Loan”) did not fund Synergy’s operations through 2019; (2) the Company could not access the second tranche of $100 million financing on or before February 28, 2018 without issuing dilutive equity; and (3) the Company could not access the third tranche of the CRG Loan if and when needed because terms were required to be met in order to access those tranches. On September 5, 2017, Synergy issued a press release announcing it had closed on a “non-dilutive” $300 million loan from CRG Partners III L.P., which would be available to Synergy “when needed” and fund the Company’s operations through 2019. On November 14, 2017, Synergy revealed that terms of the loan agreement, omitted from prior statements regarding the loan, prevented it from accessing $200 million of the loan without conducting a dilutive secondary offering or offerings of shares to raise cash and, as such, the Company was conducting a secondary offering of its shares.
If you suffered a loss in Synergy you have until April 10, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/synergy-pharmaceuticals-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]


Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Jetstar to Charge for Overhead Cabin Bags From February
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
DeepSeek to Raise AI API Prices as Demand for New Models Surges
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 



